References
- Liewluck T, Kao JC, Mauermann ML. PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies. J Immunother. 2018 May;41(4):208–11.
- March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: A fatal case report. J Oncol Pharm Pr. 2018 Mar;24(2):146–9.
- Reynolds KL, Guidon AC. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Oncologist. 2019 Apr;24(4):435–43.
- Erkilinc B, Karagozlu E, Uludag B. S52. A case of myasthenia gravis related to use of pembrolizumab. Clin Neurophysiol. 2018 May 1;129:e161.
- Hibino M, Maeda K, Horiuchi S, Fukuda M, Kondo T. Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer. Respirol Case Rep. 2018 Oct;6 (7):e00355.
- Huh SY, Shin SH, Kim MK, Lee SY, Son KH, Shin HY. Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer. J Clin Neurol. 2018 Jan;14(1):115–7.
- Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016;107(7):1055–
- Neilan TG, Rothenberg ML, Amiri-Kordestani L, Sullivan RJ, Steingart RM, Gregory W, et al. Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. Oncologist. 2018 Aug;23(8):874–8.
- Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017 Sep 12;89(11):1127–34.
- Suzuki S, Utsugisawa K, Yoshikawa H, Motomura M, Matsubara S, Yokoyama K, et al. Autoimmune Targets of Heart and Skeletal Muscles in Myasthenia GravisHeart and Skeletal Muscle Targeting in Myasthenia Gravis. JAMA Neurol. 2009;66(11):1334–8.
- Yokoyama S, Miyoshi H. Thymic tumors and immune checkpoint inhibitors. J Thorac Dis. 2018 May;10(Suppl 13):S1509-s1515.
- Cho J, Kim HS, Ku BM, Choi YL, Cristescu R, Han J, et al. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol. 2018 Jun 15;Jco2017773184.
- Mygland Å, Vincent A, Newsom-Davis J, Kaminski H, Zorzato F, Agius M, et al. Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia. JAMA Neurol. 2000;57(4):527–31.
- Merveilleux du Vignaux C, Maury JM, Girard N. Novel Agents in the Treatment of Thymic Malignancies. Curr Treat Options Oncol. 2017 Aug 10;18(9):52.
- Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba I, et al. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. 2017 Jun;30 (6):826–33.
- Katsuya Y, Fujita Y, Horinouchi H, Ohe Y, Watanabe S, Tsuta K. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer. 2015 May;88 (2):154–9.
- Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, et al. Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors. J Thorac Oncol. 2015 Mar 1;10 (3):500–8.
- Topakian R, Zimprich F, Iglseder S, Embacher N, Guger M, Stieglbauer K, et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J Neurol. 2019 Mar 1;266(3):699– 706.
- Crusz SM, Radunovic A, Shepherd S, Shah S, Newey V, Phillips M, et al. Rituximab